The historical rank and industry rank for PCI Biotech Holding ASA's PB Ratio or its related term are showing as below:
LTS:0JGL'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.21
Current: 0.21
During the past 13 years, PCI Biotech Holding ASA's highest PB Ratio was 0.21. The lowest was 0.00. And the median was 0.00.
LTS:0JGL's PB Ratio is not ranked
in the Biotechnology industry.
Industry Median: 2.97
vs LTS:0JGL: 0.21
During the past 12 months, PCI Biotech Holding ASA's average Book Value Per Share Growth Rate was -60.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -40.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -39.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -0.60% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of PCI Biotech Holding ASA was 103.20% per year. The lowest was -53.90% per year. And the median was -26.65% per year.
Back to Basics: PB Ratio
PCI Biotech Holding ASA (LTS:0JGL) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, PCI Biotech Holding ASA's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PCI Biotech Holding ASA PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's PB Ratio distribution charts can be found below:
* The bar in red indicates where PCI Biotech Holding ASA's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
PCI Biotech Holding ASA (LTS:0JGL) has a PB Ratio of 0.21 as of Jul. 04, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on PCI Biotech Holding ASA and its competitors.
Is PCI Biotech Holding ASA's PB Ratio too high?
PCI Biotech Holding ASA's current PB Ratio is 0.21. The Biotechnology industry median PB Ratio is 2.97. PCI Biotech Holding ASA's value of 0.21 is 92.9% below this industry median.
How does PCI Biotech Holding ASA's PB Ratio compare to VRTX and REGN?
PCI Biotech Holding ASA's PB Ratio of 0.21 can be compared against companies in the Biotechnology industry. The industry median PB Ratio is 2.97. PCI Biotech Holding ASA's value of 0.21 is 92.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.97, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PCI Biotech Holding ASA's current PB Ratio of 0.21 is 92.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on PCI Biotech Holding ASA and its competitors. For the Biotechnology industry, the median PB Ratio is 2.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PCI Biotech Holding ASA's current PB Ratio is 0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PCI Biotech Holding ASA stock overvalued right now?
PCI Biotech Holding ASA (LTS:0JGL) has a current PB Ratio of 0.21. The current PB Ratio is 0.21 and 92.9% below the Biotechnology industry median of 2.97. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For PCI Biotech Holding ASA (LTS:0JGL), the current PB Ratio is 0.21 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0JGL has been successfully added to your 